ClinicalTrials.gg
CompletedNCT03213457Updated Dec 20, 2024Results posted

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

A Phase 3 interventional study of Estradiol/Norethindrone Acetate and Placebo for Elagolix in Endometriosis, sponsored by AbbVie. Completed at 197 sites in 3 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
681
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Endometriosis by AbbVie — none open to participants now, 1 under way, 1 of them phase 3. Endometriosis · AbbVie.

Enrollment
4th of 16
681 · median 195
Started
2017
with 1 other
Phase 3
7 of 21
none open now
Registered
15th of 21
by date

Among the 21 studies in Endometriosis by AbbVie, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 15th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

None of the 21 studies in Endometriosis by AbbVie is open now. The open studies under Endometriosis, anywhere →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Endometriosis by AbbVie as a file.
02

Study summary

The objective of this study is to evaluate safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female participants including the safety and efficacy of elagolix in combination with concomitant hormonal add-back therapy.

03

Conditions studied

  • Endometriosis

Keywords

  • Elagolix
  • Endometriosis associated pain
  • Dysmenorrhea (DYS)
  • Non-menstrual pelvic pain (NMPP)
  • ORILISSA
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is a premenopausal female 18 to 49 years of age (inclusive) at the time of Screening.
  • Participant has a documented surgical diagnosis (e.g., laparoscopy or laparotomy) of endometriosis established by visualization within 10 years prior to entry into Washout or Screening.
  • Participant must agree to use only protocol specified rescue analgesics during the Screening and Treatment Periods for endometriosis-associated pain.
  • Participant must have the following documented in the e-Diary during the last 35 days prior to Study Day 1:

    1. At least 2 days of "moderate" or "severe" dysmenorrhea (DYS) AND either
    2. At least 2 days of "moderate" or "severe" non-menstrual pelvic pain (NMPP) and an average NMPP score of at least 1.0, OR
    3. At least 4 days of "moderate" or "severe" NMPP and an average NMPP score of at least 0.5.

Exclusion criteria

Exclusion Criteria:

  • Participant has chronic pelvic pain that is not caused by endometriosis, that requires chronic analgesic therapy, which would interfere with the assessment of endometriosis-related pain.
  • Participant is using any systemic for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over-the-counter and prescription topical, inhaled or intranasal corticosteroids are allowed.
  • Participant has a history of any major depression or post-traumatic stress disorder (PTSD) within 2 years of the screening visit or other major psychiatric disorder at any time.
  • Participant has a history of suicide attempts or answered "yes" to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) within the last 1 year at Screening or prior to randomization on Day 1.
  • Participant has any history of osteoporosis or other metabolic bone disease or any condition that would interfere with obtaining adequate dual energy x-ray absorptiometry (DXA) measurements
  • Screening DXA results of the lumbar spine (L1-L4), femoral neck or total hip bone mineral density (BMD) corresponding to less than 2.0 or more standard deviations below normal.
  • Participant has either:

    1. a newly diagnosed, medical condition that requires therapeutic intervention (e.g., new onset hypertension), that has not been stabilized 30 days prior to randomization on Day 1 OR
    2. a clinically significant medical condition that is anticipated to require intervention during the course of study participation (e.g., anticipated major elective surgery) OR
    3. an unstable medical condition that makes the subject an unsuitable candidate for the study in the opinion of the Investigator, (including, but not limited to, uncontrolled diabetes mellitus, uncontrolled hypertension, epilepsy requiring anti-epileptic medication, unstable angina, confirmed inflammatory bowel disease, hyperprolactinemia, clinically significant infection or injury).
  • Participant has any conditions with use of E2/NETA.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
681 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for elagolix administered twice daily (BID) plus placebo for estradiol/norethindrone acetate (E2/NETA) administered once daily (QD) for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.

    Drug: Placebo for Elagolix · Drug: Placebo for E2/NETA

  • Experimental
    Elagolix / Elagolix + E2/NETA

    Elagolix 200 mg BID alone for the first 6 months of the 12-month placebo-controlled Treatment Period and elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the second 6 months, followed by elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.

    Drug: Estradiol/Norethindrone Acetate · Drug: Elagolix

  • Experimental
    Elagolix + E2/NETA

    Elagolix 200 mg BID + E2/NETA 1 mg/0.5 mg QD for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.

    Drug: Estradiol/Norethindrone Acetate · Drug: Elagolix

Interventions

  • DrugEstradiol/Norethindrone Acetate

    Drug pages: Estradiol · Norethindrone Acetate

    Tablets

    Also known as: Activella, E2/NETA

  • DrugPlacebo for Elagolix

    Tablet

  • Tablet

    Also known as: ABT-620, Elagolix Sodium, ORILISSA

  • DrugPlacebo for E2/NETA

    Tablets

06

What researchers measure

Primary outcomes

  1. Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment

    Participants recorded rescue analgesic use for endometriosis-associated pain daily and DYS (pain during menstruation ) and its impact on daily activities each day of their period in an electronic diary (e-Diary). DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over 35 days prior to each visit. Response was defined as a reduction of -0.92 or more from baseline in DYS as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a \< 15% increase in average rescue analgesic pill count and no additional analgesic).

    Time frame: Month 6, Month 12

  2. Co-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment

    Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit. Response was defined as a reduction of -0.55 or greater from baseline for NMPP as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a \< 15% increase in average pill count of rescue analgesics and no additional analgesics).

    Time frame: Month 6, Month 12

Secondary outcomes

  1. Change From Baseline in DYS at Month 12 Based on Daily Assessment

    Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.

    Time frame: Baseline, Month 12

  2. Change From Baseline in DYS at Month 6 Based on Daily Assessment

    Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: 0: No discomfort 1. Mild discomfort but I was easily able to do the things I usually do 2. Moderate discomfort or pain that made it difficult to do some of the things I usually do 3. Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.

    Time frame: Baseline, Month 6

  3. Change From Baseline in DYS at Month 3 Based on Daily Assessment

    Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: 0: No discomfort 1. Mild discomfort but I was easily able to do the things I usually do 2. Moderate discomfort or pain that made it difficult to do some of the things I usually do 3. Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.

    Time frame: Baseline, Month 3

  4. Change From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment

    Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.

    Time frame: Baseline, Month 12

  5. Change From Baseline in NMPP at Month 6 Based on Daily Assessment

    Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.

    Time frame: Baseline, Month 6

  6. Change From Baseline in NMPP at Month 3 Based on Daily Assessment

    Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.

    Time frame: Baseline, Month 3

  7. Change From Baseline to Month 6 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score

    The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue.

    Time frame: Baseline, Month 6

  8. Change From Baseline in Dyspareunia (DYSP) at Month 12 Based on Daily Assessment

    Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.

    Time frame: Baseline, Month 12

  9. Change From Baseline in DYSP at Month 6 Based on Daily Assessment

    Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.

    Time frame: Baseline, Month 6

  10. Change From Baseline in DYSP at Month 3 Based on Daily Assessment

    Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.

    Time frame: Baseline, Month 3

  11. Change From Baseline to Month 12 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score

    The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue.

    Time frame: Baseline, Month 12

  12. Change From Baseline in Endometriosis-Associated Pain Score at Month 12 Assessed With Numeric Rating Scale (NRS)

    The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.

    Time frame: Baseline, Month 12

  13. Change From Baseline in Endometriosis-Associated Pain Score at Month 6 Assessed With NRS

    The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.

    Time frame: Baseline, Month 6

  14. Change From Baseline in Endometriosis-Associated Pain Score at Month 3 Assessed With NRS

    The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.

    Time frame: Baseline, Month 3

07

Results

Posted Apr 20, 2021

Participant flow

A total of 679 subjects were treated at 137 sites in 2 countries (US \[including Puerto Rico\] and Canada). Of the 679 subjects who were treated on study, 299 subjects discontinued study drug prematurely during the Placebo-Controlled Treatment Period and 240 discontinued study drug prematurely during the Open-Label Treatment Period.

Screening Period
Participant flow — Screening Period
MilestonePlaceboElagolix / Elagolix + E2/NETAElagolix + E2/NETA
Started19498389
Completed19397389
Not completed110
Withdrew: Withdrawal by subject010
Withdrew: Other100
Double-Blind Period
Participant flow — Double-Blind Period
MilestonePlaceboElagolix / Elagolix + E2/NETAElagolix + E2/NETA
Started19397389
Completed15785337
Not completed361252
Withdrew: Adverse event327
Withdrew: Withdrawal by subject14214
Withdrew: Lost to follow-up239
Withdrew: Requires surgery or invasive intervention for treatment of endometriosis201
Withdrew: Non-compliance with study procedures024
Withdrew: Pregnancy500
Withdrew: Other10317
Open-Label Period
Participant flow — Open-Label Period
MilestonePlaceboElagolix / Elagolix + E2/NETAElagolix + E2/NETA
Started10659215
Completed9048170
Not completed161145
Withdrew: Adverse event122
Withdrew: Withdrawal by subject12524
Withdrew: Lost to follow-up128
Withdrew: Requires surgery or invasive intervention for treatment of endometriosis002
Withdrew: Non-compliance with study procedures112
Withdrew: Exclusionary medications001
Withdrew: Other116
Follow-Up Period
Participant flow — Follow-Up Period
MilestonePlaceboElagolix / Elagolix + E2/NETAElagolix + E2/NETA
Started19498389
Completed10251185
Not completed9247204
Withdrew: Adverse event16837
Withdrew: Withdrawal by subject181155
Withdrew: Lost to follow-up281550
Withdrew: Requires surgery or invasive intervention for treatment of endometriosis312
Withdrew: Non-compliance with study procedures416
Withdrew: Pregnancy7018
Withdrew: Exclusionary medications115
Withdrew: Covid-19 logistical restrictions100
Withdrew: Other141031

Outcome measures

PrimaryCo-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment

Participants recorded rescue analgesic use for endometriosis-associated pain daily and DYS (pain during menstruation ) and its impact on daily activities each day of their period in an electronic diary (e-Diary). DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over 35 days prior to each visit. Response was defined as a reduction of -0.92 or more from baseline in DYS as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a \< 15% increase in average rescue analgesic pill count and no additional analgesic).

Time frame:
Month 6, Month 12
Reported as:
Number · percentage of participants
Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment
percentage of participantsPlaceboElagolix + E2/NETA
Month 623.7 (17.64 to 29.73)62.8 (57.93 to 67.60)
Month 1229.1 (22.62 to 35.58)63.8 (58.97 to 68.69)
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · Regression, Logistic · p = < 0.001 (P-value for test of difference is from a logistic regression model including treatment as the main effect and baseline value as a covariate.) · Odds ratio (or): 5.51 · 95% CI 3.711 to 8.176
  • Placebo vs Elagolix + E2/NETA · Regression, Logistic · p = < 0.001 (P-value for test of difference is from a logistic regression model including treatment as the main effect and baseline value as a covariate.) · Odds ratio (or): 4.33 · 95% CI 2.968 to 6.331
PrimaryCo-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment

Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit. Response was defined as a reduction of -0.55 or greater from baseline for NMPP as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a \< 15% increase in average pill count of rescue analgesics and no additional analgesics).

Time frame:
Month 6, Month 12
Reported as:
Number · percentage of participants
Co-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment
percentage of participantsPlaceboElagolix + E2/NETA
Month 636.8 (29.98 to 43.70)51.3 (46.30 to 56.30)
Month 1242.3 (35.28 to 49.37)54.3 (49.22 to 59.29)
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · Regression, Logistic · p = < 0.001 (P-value for test of difference is from a logistic regression model including treatment as the main effect and baseline value as a covariate.) · Odds ratio (or): 1.82 · 95% CI 1.275 to 2.605
  • Placebo vs Elagolix + E2/NETA · Regression, Logistic · p = 0.007 (P-value for test of difference is from a logistic regression model including treatment as the main effect and baseline value as a covariate.) · Odds ratio (or): 1.63 · 95% CI 1.146 to 2.326
SecondaryChange From Baseline in DYS at Month 12 Based on Daily Assessment

Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in DYS at Month 12 Based on Daily Assessment
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in DYS at Month 12 Based on Daily Assessment-0.73 ± 0.077-1.73 ± 0.055
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · mixed model repeated measures (MMRM) · p = < 0.001 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Least squares (ls) mean of difference: -0.99 · 95% CI -1.180 to -0.809
SecondaryChange From Baseline in DYS at Month 6 Based on Daily Assessment

Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: 0: No discomfort 1. Mild discomfort but I was easily able to do the things I usually do 2. Moderate discomfort or pain that made it difficult to do some of the things I usually do 3. Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in DYS at Month 6 Based on Daily Assessment
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in DYS at Month 6 Based on Daily Assessment-0.62 ± 0.072-1.64 ± 0.050
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = < 0.001 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -1.02 · 95% CI -1.190 to -0.845
SecondaryChange From Baseline in DYS at Month 3 Based on Daily Assessment

Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: 0: No discomfort 1. Mild discomfort but I was easily able to do the things I usually do 2. Moderate discomfort or pain that made it difficult to do some of the things I usually do 3. Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.

Time frame:
Baseline, Month 3
Reported as:
Least squares mean · score on a scale
Change From Baseline in DYS at Month 3 Based on Daily Assessment
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in DYS at Month 3 Based on Daily Assessment-0.56 ± 0.069-1.54 ± 0.049
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = < 0.001 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -0.99 · 95% CI -1.156 to -0.823
SecondaryChange From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment

Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment-0.64 ± 0.060-0.86 ± 0.042
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = 0.002 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -0.22 · 95% CI -0.367 to -0.080
SecondaryChange From Baseline in NMPP at Month 6 Based on Daily Assessment

Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in NMPP at Month 6 Based on Daily Assessment
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in NMPP at Month 6 Based on Daily Assessment-0.57 ± 0.051-0.78 ± 0.036
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = < 0.001 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -0.21 · 95% CI -0.329 to -0.085
SecondaryChange From Baseline in NMPP at Month 3 Based on Daily Assessment

Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.

Time frame:
Baseline, Month 3
Reported as:
Least squares mean · score on a scale
Change From Baseline in NMPP at Month 3 Based on Daily Assessment
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in NMPP at Month 3 Based on Daily Assessment-0.49 ± 0.046-0.65 ± 0.032
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = 0.004 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -0.16 · 95% CI -0.270 to -0.050
SecondaryChange From Baseline to Month 6 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score

The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · T-score
Change From Baseline to Month 6 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score
T-scorePlaceboElagolix + E2/NETA
Change From Baseline to Month 6 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score-4.71 ± 0.739-7.22 ± 0.514
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · ANCOVA · p = 0.005 (P-value for test of difference at each post-baseline time point is from an ANCOVA model with treatment as the main effect and baseline as a covariate.) · Ls mean of difference: -2.51 · 95% CI -4.283 to -0.746
SecondaryChange From Baseline in Dyspareunia (DYSP) at Month 12 Based on Daily Assessment

Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dyspareunia (DYSP) at Month 12 Based on Daily Assessment
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in Dyspareunia (DYSP) at Month 12 Based on Daily Assessment-0.60 ± 0.079-0.70 ± 0.058
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = 0.284 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -0.11 · 95% CI -0.298 to 0.088
SecondaryChange From Baseline in DYSP at Month 6 Based on Daily Assessment

Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in DYSP at Month 6 Based on Daily Assessment
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in DYSP at Month 6 Based on Daily Assessment-0.54 ± 0.076-0.63 ± 0.053
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = 0.286 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -0.10 · 95% CI -0.279 to 0.083
SecondaryChange From Baseline in DYSP at Month 3 Based on Daily Assessment

Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.

Time frame:
Baseline, Month 3
Reported as:
Least squares mean · score on a scale
Change From Baseline in DYSP at Month 3 Based on Daily Assessment
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in DYSP at Month 3 Based on Daily Assessment-0.40 ± 0.064-0.62 ± 0.045
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = 0.005 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -0.22 · 95% CI -0.375 to -0.066
SecondaryChange From Baseline to Month 12 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score

The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · T-score
Change From Baseline to Month 12 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score
T-scorePlaceboElagolix + E2/NETA
Change From Baseline to Month 12 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score-6.43 ± 0.949-8.92 ± 0.665
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · ANCOVA · p = 0.032 (P-value for test of difference at each post-baseline time point is from an ANCOVA model with treatment as the main effect and baseline as a covariate.) · Ls mean of difference: -2.49 · 95% CI -4.773 to -0.216
SecondaryChange From Baseline in Endometriosis-Associated Pain Score at Month 12 Assessed With Numeric Rating Scale (NRS)

The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Endometriosis-Associated Pain Score at Month 12 Assessed With Numeric Rating Scale (NRS)
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in Endometriosis-Associated Pain Score at Month 12 Assessed With Numeric Rating Scale (NRS)-3.25 ± 0.263-4.39 ± 0.186
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = < 0.001 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -1.14 · 95% CI -1.774 to -0.508
SecondaryChange From Baseline in Endometriosis-Associated Pain Score at Month 6 Assessed With NRS

The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in Endometriosis-Associated Pain Score at Month 6 Assessed With NRS
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in Endometriosis-Associated Pain Score at Month 6 Assessed With NRS-2.74 ± 0.248-4.12 ± 0.174
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = < 0.001 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -1.38 · 95% CI -1.978 to -0.788
SecondaryChange From Baseline in Endometriosis-Associated Pain Score at Month 3 Assessed With NRS

The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.

Time frame:
Baseline, Month 3
Reported as:
Least squares mean · score on a scale
Change From Baseline in Endometriosis-Associated Pain Score at Month 3 Assessed With NRS
score on a scalePlaceboElagolix + E2/NETA
Change From Baseline in Endometriosis-Associated Pain Score at Month 3 Assessed With NRS-2.33 ± 0.225-3.79 ± 0.161
Statistical analysis
  • Placebo vs Elagolix + E2/NETA · MMRM · p = < 0.001 (P value for the test of the difference is from an MMRM with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, and the continuous fixed covariate of baseline pain score, and random effect for participant.) · Ls mean of difference: -1.46 · 95% CI -2.002 to -0.915

Adverse events

Collected over All-cause mortality: from randomization through the end of the Treatment Period (Month 12). Adverse Events(AEs): From first dose of study drug through the end of the Treatment Period (Month 12).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SCR_Placebo0/194 (0%)0/194 (0%)1/194 (0.5%)
SCR_Elagolix0/98 (0%)0/98 (0%)0/98 (0%)
SCR_Elagolix_and_E2-NETA0/389 (0%)1/389 (0.3%)1/389 (0.3%)
DB_Placebo0/194 (0%)8/194 (4.1%)89/194 (45.9%)
DB_Elagolix0/98 (0%)2/98 (2%)74/98 (75.5%)
DB_Elagolix_and_E2-NETA0/389 (0%)14/389 (3.6%)236/389 (60.7%)
OL_Placebo_to_ELA_and_E2-NETA0/106 (0%)7/106 (6.6%)60/106 (56.6%)
OL_ELA_to_ELA_and_E2-NETA0/59 (0%)2/59 (3.4%)32/59 (54.2%)
OL_ELA_and_E2-NETA_to_ELA_and_E2-NETA0/215 (0%)10/215 (4.7%)125/215 (58.1%)
FU_Placebo_to_ELA_and_E2-NETA0/194 (0%)2/194 (1%)2/194 (1%)
FU_ELA_to_ELA_and_E2-NETA0/98 (0%)0/98 (0%)3/98 (3.1%)
FU_ELA_and_E2-NETA_to_ELA_and_E2-NETA0/389 (0%)1/389 (0.3%)6/389 (1.5%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventSCR_PlaceboSCR_ElagolixSCR_Elagolix_and_E2-NETADB_PlaceboDB_ElagolixDB_Elagolix_and_E2-NETAOL_Placebo_to_ELA_and_E2-NETAOL_ELA_to_ELA_and_E2-NETAOL_ELA_and_E2-NETA_to_ELA_and_E2-NETAFU_Placebo_to_ELA_and_E2-NETAFU_ELA_to_ELA_and_E2-NETAFU_ELA_and_E2-NETA_to_ELA_and_E2-NETA
ABDOMINAL PAIN LOWERGastrointestinal disorders0/1940/980/3890/1940/980/3890/1061/590/2150/1940/980/389
NAUSEAGastrointestinal disorders0/1940/980/3890/1940/980/3890/1061/590/2150/1940/980/389
OVARIAN CYST RUPTUREDReproductive system and breast disorders0/1940/980/3890/1940/980/3890/1061/590/2150/1940/980/389
ENDOMETRIOSISReproductive system and breast disorders0/1940/980/3892/1941/980/3890/1060/591/2150/1940/980/389
INTESTINAL PERFORATIONGastrointestinal disorders0/1940/980/3890/1941/980/3890/1060/590/2150/1940/980/389
ABSCESS INTESTINALInfections and infestations0/1940/980/3890/1941/980/3890/1060/590/2150/1940/980/389
FOOD POISONINGGastrointestinal disorders0/1940/980/3890/1940/980/3891/1060/590/2150/1940/980/389
APPENDICITISInfections and infestations0/1940/980/3890/1940/980/3891/1060/590/2150/1940/980/389
GASTROENTERITISInfections and infestations0/1940/980/3890/1940/980/3891/1060/590/2150/1940/980/389
FLANK PAINMusculoskeletal and connective tissue disorders0/1940/980/3890/1940/980/3891/1060/590/2150/1940/980/389
Most frequent other events
Showing 10 of 26
Most frequent other events
EventSCR_PlaceboSCR_ElagolixSCR_Elagolix_and_E2-NETADB_PlaceboDB_ElagolixDB_Elagolix_and_E2-NETAOL_Placebo_to_ELA_and_E2-NETAOL_ELA_to_ELA_and_E2-NETAOL_ELA_and_E2-NETA_to_ELA_and_E2-NETAFU_Placebo_to_ELA_and_E2-NETAFU_ELA_to_ELA_and_E2-NETAFU_ELA_and_E2-NETA_to_ELA_and_E2-NETA
HOT FLUSHVascular disorders0/1940/980/38914/19443/9869/3898/1062/5910/2150/1940/980/389
NAUSEAGastrointestinal disorders1/1940/980/38912/19416/9851/3899/1062/5912/2150/1940/981/389
COVID-19Infections and infestations0/1940/980/3890/1940/980/3899/1067/5929/2151/1940/982/389
HEADACHENervous system disorders1/1940/980/38910/19413/9846/3898/1064/597/2150/1940/981/389
NIGHT SWEATSSkin and subcutaneous tissue disorders0/1940/980/3896/19413/9824/3893/1060/595/2150/1940/980/389
SINUSITISInfections and infestations0/1940/980/38913/19410/9832/3899/1065/5918/2150/1941/980/389
BRONCHITISInfections and infestations0/1940/980/3896/1943/9811/3895/1066/599/2150/1940/980/389
BONE DENSITY DECREASEDInvestigations0/1940/980/3890/1940/985/3897/1066/5921/2150/1941/981/389
URINARY TRACT INFECTIONInfections and infestations0/1940/980/3899/1949/9815/3896/1065/5916/2151/1941/980/389
INSOMNIAPsychiatric disorders0/1940/980/3891/1949/9813/3895/1061/596/2150/1940/981/389

Baseline characteristics

Full Analysis Set: all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboElagolix / Elagolix + E2/NETAElagolix + E2/NETATotal
Mean33.1 ± 6.7232.5 ± 6.4432.3 ± 6.7432.5 ± 6.69
Sex/Gender, Customized
Sex/Gender, Customized(Participants)PlaceboElagolix / Elagolix + E2/NETAElagolix + E2/NETATotal
Female19397389679
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboElagolix / Elagolix + E2/NETAElagolix + E2/NETATotal
Hispanic or Latino371158106
Not Hispanic or Latino15686331573
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboElagolix / Elagolix + E2/NETAElagolix + E2/NETATotal
American Indian or Alaska Native1012
Asian0044
Native Hawaiian or Other Pacific Islander0011
Black or African American31194999
White15974328561
More than one race24612
Unknown or Not Reported0000
08

Study locations

197 sites
  • Central Research Associates /ID# 163087
    Birmingham, Alabama 35205, United States
  • Alabama Clinical Therapeutics, LLC /ID# 145503
    Birmingham, Alabama 35235-3430, United States
  • Alabama Clinical Therapeutics, LLC /ID# 151468
    Birmingham, Alabama 35235-3430, United States
  • Southern Women's Specialists PC /ID# 148750
    Fairhope, Alabama 36532-3029, United States
  • Women's Health Alliance of Mobile /ID# 150083
    Mobile, Alabama 36604-1410, United States
  • University of South Alabama /ID# 148774
    Mobile, Alabama 36604-3302, United States
  • Mobile, Ob-Gyn, P.C. /ID# 145364
    Mobile, Alabama 36608, United States
  • Mesa Obstetricians and Gynecologists /ID# 147320
    Mesa, Arizona 85209, United States
  • Arizona Research Assoc /ID# 161703
    Tucson, Arizona 85712, United States
  • Eclipse Clinical Research /ID# 155600
    Tucson, Arizona 85745, United States
  • Unity Health- Searcy Medical Center /ID# 203674
    Searcy, Arkansas 72143-4802, United States
  • Core Healthcare Group /ID# 149321
    Cerritos, California 90703, United States
  • HRC Fertility /ID# 154143
    Encino, California 91436, United States
  • Glendale Adventist Medical Ctr /ID# 160530
    Glendale, California 91206, United States
  • HCP Clinical Research LLC /ID# 152045
    Huntington Beach, California 92646, United States
  • Alliance Research Centers /ID# 151240
    Irvine, California 92612-1245, United States
  • Long Beach Clinical Trial Serv /ID# 152428
    Long Beach, California 90806, United States
  • Olympia Clinical Trials /ID# 202325
    Los Angeles, California 90036-4667, United States
  • California Medical Research As /ID# 154746
    Northridge, California 91324, United States
  • Futura Research, Org /ID# 145406
    Norwalk, California 90650, United States
  • Huntington Medical Foundation /ID# 154750
    Pasadena, California 91105, United States
  • Northern California Research /ID# 159753
    Sacramento, California 95821-2640, United States
  • Precision Research Institute - San Diego /ID# 152557
    San Diego, California 92114-3643, United States
  • MD Strategies Research Centers /ID# 152429
    San Diego, California 92119, United States
  • Alta California Medical Group /ID# 155706
    Simi Valley, California 93065, United States
  • Downtown Womens Health Care /ID# 147955
    Denver, Colorado 80209, United States
  • Advanced Women's Health Institute /ID# 145396
    Greenwood Village, Colorado 80111, United States
  • Red Rocks OB/GYN /ID# 145325
    Lakewood, Colorado 80228-1810, United States
  • The Women's Health Group - Thornton /ID# 203707
    Thornton, Colorado 80229-4385, United States
  • James A. Simon, MD, PC /ID# 145480
    Washington, District of Columbia 20036, United States
  • Helix Biomedics, LLC /ID# 147108
    Boynton Beach, Florida 33436-6634, United States
  • Gulf Coast Research Group /ID# 162895
    Brandon, Florida 33510, United States
  • Olympian Clinical Research /ID# 148167
    Clearwater, Florida 33756, United States
  • Omega Research Maitland, LLC /ID# 145167
    DeBary, Florida 32713-2260, United States
  • KO Clinical Research, LLC /ID# 145410
    Fort Lauderdale, Florida 33316, United States
  • Clinical Physiology Associates /ID# 145237
    Fort Myers, Florida 33912, United States
  • Solutions Through Adv Rch /ID# 148768
    Jacksonville, Florida 32256, United States
  • Vida Clinical Research /ID# 150282
    Kissimmee, Florida 34741-2345, United States
  • Axcess Medical Center /ID# 148169
    Loxahatchee Groves, Florida 33470, United States
  • Precision Research Organization /ID# 145337
    Miami Lakes, Florida 33016-1501, United States
  • Ocean Blue Medical Research Center, Inc /ID# 145514
    Miami Springs, Florida 33166, United States
  • Genoma Research Group, Inc /ID# 152558
    Miami, Florida 33165, United States
  • Vista Health Research LLC - Miami /ID# 151455
    Miami, Florida 33176-1032, United States
  • Palmetto Professional Research /ID# 153838
    Miami, Florida 33186-1309, United States
  • Salom Tangir, LLC /ID# 148739
    Miramar, Florida 33027, United States
  • Suncoast Clinical Research /ID# 145484
    New Port Richey, Florida 34652, United States
  • Oncova Clinical Research, Inc. /ID# 148175
    Saint Cloud, Florida 34769, United States
  • Meridien Research - St Petersburg /ID# 145345
    Saint Petersburg, Florida 33709-3113, United States
  • Physician Care Clin. Res., LLC /ID# 145511
    Sarasota, Florida 34239, United States
  • Treasure Coast Research /ID# 148174
    Stuart, Florida 34996, United States
  • University of South Florida /ID# 145424
    Tampa, Florida 33612, United States
  • Stedman Clinical Trials /ID# 152554
    Tampa, Florida 33613, United States
  • Virtus Research Consultants, LLC /ID# 147101
    Wellington, Florida 33414, United States
  • Comprehensive Clinical Trials /ID# 145148
    West Palm Beach, Florida 33409, United States
  • Paramount Research Solutions /ID# 145226
    Alpharetta, Georgia 30005, United States
  • Paramount Research Solutions /ID# 149320
    Alpharetta, Georgia 30005, United States
  • Agile Clinical Research Trials /ID# 145494
    Atlanta, Georgia 30328-5532, United States
  • Atlanta Women's Research Inst /ID# 145543
    Atlanta, Georgia 30342, United States
  • Apogee Women's Health Inc. /ID# 145149
    College Park, Georgia 30349, United States
  • Columbus Regional Research Ins /ID# 159752
    Columbus, Georgia 31904, United States
  • Meridian Clinical Research, LLC /ID# 148176
    Savannah, Georgia 31406-2675, United States
  • Atlanta Gynecology Research Institute /ID# 149322
    Suwanee, Georgia 30024-7159, United States
  • Clinical Research Prime /ID# 161724
    Idaho Falls, Idaho 83404, United States
  • Womens Healthcare Assoc, DBA /ID# 148744
    Idaho Falls, Idaho 83404, United States
  • Advanced Clinical Research /ID# 147086
    Meridian, Idaho 83642, United States
  • Sonora Clinical Research /ID# 145541
    Meridian, Idaho 83646-1144, United States
  • Asr, Llc /Id# 161680
    Nampa, Idaho 83687, United States
  • Women's Health Practice, LLC /ID# 145517
    Champaign, Illinois 61820, United States
  • Affinity Clinical Research /ID# 151469
    Oak Brook, Illinois 60523, United States
  • Center for Women's Research, Inc /ID# 145486
    Palos Heights, Illinois 60463-1440, United States
  • The Advanced Gynecologic Surgery Institute - Park Ridge /ID# 151459
    Park Ridge, Illinois 60068, United States
  • American Health Network of Ind /ID# 167996
    Avon, Indiana 46123-7960, United States
  • Women's Health Advantage /ID# 145495
    Fort Wayne, Indiana 46825, United States
  • The Iowa Clinic /ID# 145409
    West Des Moines, Iowa 50266, United States
  • Womens & Family Care, LLC dba /ID# 145211
    Shawnee Mission, Kansas 66218, United States
  • PRN Professional Research Network of Kansas, LLC /ID# 151463
    Wichita, Kansas 67205, United States
  • Cypress Medical Research Ctr /ID# 147159
    Wichita, Kansas 67226, United States
  • University of Louisville /ID# 154751
    Louisville, Kentucky 40202, United States
  • Bluegrass Clinical Research /ID# 151209
    Louisville, Kentucky 40291-1988, United States
  • Clinical Trials Management, LLC - Covington /ID# 145220
    Covington, Louisiana 70433, United States
  • Clinical Trials Management, LLC - Covington /ID# 145520
    Covington, Louisiana 70433, United States
  • Horizon Research Group /ID# 148171
    Eunice, Louisiana 70535, United States
  • Praetorian Pharmaceutical Res /ID# 145405
    Marrero, Louisiana 70072, United States
  • Ochsner Baptist OB/GYN Clinic /ID# 147144
    New Orleans, Louisiana 70115, United States
  • Women Under Study, LLC /ID# 151216
    New Orleans, Louisiana 70125-1923, United States
  • Women's Health Clinic /ID# 155707
    Shreveport, Louisiana 71118-3133, United States
  • Omni Fertility and Laser Insti /ID# 145532
    Shreveport, Louisiana 71118, United States
  • Eastern Maine Medical Center /ID# 161681
    Bangor, Maine 04401, United States
  • Univ Maryland School Medicine /ID# 151739
    Baltimore, Maryland 21201, United States
  • Baltimore Suburban Health /ID# 147164
    Baltimore, Maryland 21208, United States
  • Continental Clinical Solutions /ID# 152041
    Towson, Maryland 21204, United States
  • NECCR Fall River LLC /ID# 145329
    Fall River, Massachusetts 02720-2972, United States
  • Genesis Clinical Research - Fall River /ID# 148573
    Fall River, Massachusetts 02723, United States
  • ClinSite, LLC /ID# 145314
    Ann Arbor, Michigan 48105, United States
  • Great Lakes Research Group, Inc. /ID# 145308
    Bay City, Michigan 48602, United States
  • Saginaw Valley Med Res Group /ID# 145527
    Saginaw, Michigan 48604, United States
  • Wayne State University Physician Group - Southfield /ID# 145431
    Southfield, Michigan 48034, United States
  • Prism Research /ID# 159751
    Saint Paul, Minnesota 55114, United States
  • Womens Clinic of Lincoln, P.C. /ID# 145366
    Lincoln, Nebraska 68510, United States
  • Accent Clinical Trials /ID# 147109
    Las Vegas, Nevada 89106-4017, United States

Showing the first 100 of 197 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Watts NB, Binkley N, Owens CD, Al-Hendy A, Puscheck EE, Shebley M, Schlaff WD, Simon JA. Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life. J Womens Health (Larchmt). 2021 Oct;30(10):1416-1430. doi: 10.1089/jwh.2020.8989. Epub 2021 Aug 25. PubMed 34435897 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Mar 2020, 32 months.

Results were first posted in Apr 2021, 1 year after primary completion.

Of 33 phase 3 interventional studies under Endometriosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2017
First posted
Jul 11, 2017
StartActual
Jul 7, 2017
Primary completionActual
Mar 27, 2020
CompletionActual
Dec 6, 2023
Results first posted
Apr 20, 2021
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03213457
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 11, 2017
Start date
Jul 7, 2017
Primary completion
Mar 27, 2020
Completion
Dec 6, 2023
Results posted
Apr 20, 2021
Last update
Dec 20, 2024

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Norethindrone Acetate · Elagolix

Start the discussion